Vebicorvir

Vebicorvir (ABI-H0731) 是一代乙型肝炎病毒 (HBV) 核心蛋白的抑制剂。Vebicorvir (ABI-H0731) 共价抑制两个感染模型中cccDNA 的 EC50 值为 1.84-7.3 μM。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2175.00

1740.00

- +
10mg

￥3487.00

2790.00

- +
25mg

￥7012.00

5610.00

- +
50mg

￥10800.00

8640.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx35312
CAS: 2090064-66-5
别名: ABI-H0731
分子式: C19H12F3N3O4S2
分子量: 467.44
纯度: >98%
溶解度: DMSO : 100 mg/mL (213.93 mM; Need ultrasonic)
储存: Store at -20°C
库存: 现货

Background

Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM[1].

Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68 μM, 4.95 μM, and 7.30 μM, respectively[1].Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis[1].

After i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86 ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively[1].

[1]. Qi Huang, et al. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20.